1. Home
  2. VIRT vs RVMDW Comparison

VIRT vs RVMDW Comparison

Compare VIRT & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIRT
  • RVMDW
  • Stock Information
  • Founded
  • VIRT 2008
  • RVMDW N/A
  • Country
  • VIRT United States
  • RVMDW United States
  • Employees
  • VIRT N/A
  • RVMDW 443
  • Industry
  • VIRT Investment Bankers/Brokers/Service
  • RVMDW
  • Sector
  • VIRT Finance
  • RVMDW
  • Exchange
  • VIRT Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • VIRT N/A
  • RVMDW N/A
  • IPO Year
  • VIRT 2015
  • RVMDW N/A
  • Fundamental
  • Price
  • VIRT $32.84
  • RVMDW $0.10
  • Analyst Decision
  • VIRT Buy
  • RVMDW
  • Analyst Count
  • VIRT 7
  • RVMDW 0
  • Target Price
  • VIRT $29.50
  • RVMDW N/A
  • AVG Volume (30 Days)
  • VIRT 1.6M
  • RVMDW N/A
  • Earning Date
  • VIRT 10-24-2024
  • RVMDW N/A
  • Dividend Yield
  • VIRT 2.92%
  • RVMDW N/A
  • EPS Growth
  • VIRT 45.33
  • RVMDW N/A
  • EPS
  • VIRT 1.98
  • RVMDW N/A
  • Revenue
  • VIRT $1,832,110,000.00
  • RVMDW N/A
  • Revenue This Year
  • VIRT N/A
  • RVMDW N/A
  • Revenue Next Year
  • VIRT $0.40
  • RVMDW N/A
  • P/E Ratio
  • VIRT $16.60
  • RVMDW N/A
  • Revenue Growth
  • VIRT 5.89
  • RVMDW N/A
  • 52 Week Low
  • VIRT $16.02
  • RVMDW N/A
  • 52 Week High
  • VIRT $33.55
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • VIRT 62.09
  • RVMDW N/A
  • Support Level
  • VIRT $31.49
  • RVMDW N/A
  • Resistance Level
  • VIRT $32.65
  • RVMDW N/A
  • Average True Range (ATR)
  • VIRT 0.70
  • RVMDW 0.00
  • MACD
  • VIRT 0.12
  • RVMDW 0.00
  • Stochastic Oscillator
  • VIRT 78.61
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: